Similar effects of ERβ agonist treatment on lymphoma growth in wild-type and ERβ⁻/⁻mice. Male C57/Bl6J wild-type and ERβ^−/− (BERKO) mice were subcutaneously grafted with 2 × 10⁶ ERβ-positive EG7 lymphoma cells. Starting from day 7 after tumor cell grafting, animals were treated subcutaneously daily with the ERβ-selective agonist DPN (12.5 μmol/kg per day) or vehicle. The groups consisted of 5 vehicle-treated wild-type (●), 6 DPN-treated wild-type (▪), 6 vehicle-treated ERβ^−/− (▼), and 5 DPN-treated ERβ^−/− (▲) mice. For wild-type mice, vehicle vs DPN: ***P < .001. For ERβ^−/− mice, vehicle vs DPN: ^¶P < .05 and ^¶¶¶P < .001. No significant difference was observed between DPN-treated wild-type and ERβ^−/− mice or between wild-type and ERβ^−/− vehicle-treated mice. WT, wild-type.